The European Committee for Medicinal Products for Human Use has issued a recommendation to the European Commission to allow the sale of Tafacitamab in combination with Lenalidomide, developed by Incyte and MorphoSys. The drug is intended to treat adult patients with relapsed or refractory diffuse large cell lymphoma. The CHMP opinion is currently under review by the European Commission.